Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats

Acta Pharmacologica Sinica

Volumn 33, Issue 6, 2012, Pages 791-797

  Wang, Jian Qing ^a   Zou, Yu Hong ^b   Huang, Cheng ^a   Lu, Chao ^a   Zhang, Lei ^a   Jin, Yong ^a   Lü, Xiong Wen ^a   Liu, Li Ping ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b INDIANA UNIVERSITY   (United States)

Author keywords

antioxidant; CYP2E1; lipid metabolism; mitochondria; non alcoholic steatohepatitis; tiopronin; ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOCHROME P450 2E1; FATTY ACID; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MESSENGER RNA; SUPEROXIDE DISMUTASE; TIOPRONIN; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL DEGENERATION; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FEEDING; IMMUNOBLOTTING; INFLAMMATORY CELL; LIPID DIET; LIPID METABOLISM; LIVER; LIVER CELL; LIVER HOMOGENATE; MALE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; CHOLESTEROL; CYTOCHROME P-450 CYP2E1; DIET, HIGH-FAT; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; LIPID PEROXIDATION; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIOPRONIN; TRIGLYCERIDES; URSODEOXYCHOLIC ACID;

EID: 84862551977     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.19     Document Type: Article

References (38)

1. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114: 842-5.
2. Te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med 2004; 15: 10-21.
3. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol 2005; 100: 1072-81.
4. Stratopoulos C, Papakonstantinou A, Terzis I, Spiliadi C, Dimitriades G, Komesidou V, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15: 1154-60.
5. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
6. Dioguardi N, Ideo G, De Franchis R, Ronchi G. Controlled clinical trial of 2-mercapto-propionyl-glycine in chronic hepatopathies. Minerva Med 1976; 67: 676-81.
7. Ichikawa H, Imaizumi K, Tazawa Y, Obara Y, Ishikawa Y, Tobari I, et al. Effect of tiopronin on senile cataracts. A double-blind clinical study. Ophthalmologica 1980; 180: 293-8.
8. Sany J, Combe B, Verdie-Petibon D, Tagemouati A, Daures JP. Longterm tolerability of tiopronin (Acadione) in the treatment of rheumatoid arthritis. Apropos of 140 personal cases. Rev Rhum Mal Osteoartic 1990; 57: 105-11.
9. Ichida F, Shibasaki K, Takino T, Suzuki H, Fujisawa K, Inoue K, et al. Therapeutic effects of tiopronin on chronic hepatitis: A double-blind clinical study. J Int Med Res 1982; 10: 325-32.
10. Kim ES, Glisson BS. Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res 2003; 114: 295-314.
11. Hirayama C, Kishimoto Y, Wakushima T, Murawaki Y. Mechanism of the protective action of thiol compounds in ethanol-induced liver injury. Biochem Pharmacol 1983; 32: 321-5.
12. Yilong C. Clinical evaluation on the effect of tiopronin in nonalcoholic steatohepatitis. China Modern Doctor 2008; 46: 37-8.
13. Surrenti C, Arcangeli A, Casini A. The antisteatosic activity of 2-MPG (Thiola). Study with the (BSF) dynamic test and with liver biopsy before and after the treatment. Minerva Med 1978; 69: 4251-6.
14. Ljubuncic P, Tanne Z, Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000; 45: 1921-8.
15. Buko VU, Lukivskaya OY, Zavodnik LV, Sadovnichy VV, Petushok NE, Tauschel ND. Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by gamma-irradiation. Ukr Biokhim Zh 2002; 74: 88-92.
16. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH. Therapy of NAFLD: Antioxidants and cytoprotective agents. J Clin Gastroenterol 2006; 40: S51-60.
17. Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009; 29: 1184-8.
18. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46.
19. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholinduced steatohepatitis: A pilot study. epatology 1996; 23: 1464-7.
20. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamine in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-43.
21. Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 2005; 11: 2346-50.
22. Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, et al. High-fat emulsioninduced rat model of nonalcoholic steatohepatitis. Life Sci 2006; 79: 1100-7.
23. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
24. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 2003; 18: 1272-82.
25. Avni Y, Shirin H, Aeed H, Shahmurov M, Birkenfeld S, Bruck R. Thioacetamide-induced hepatic damage in a rat nutritional model of steatohepatitis. Hepatol Res 2004; 30: 141-7.
26. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
27. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
28. Mavrelis PG, Ammon HV, Gleysteen JJ, Komorowski RA, Charaf UK. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology 1983; 3: 226-31.
29. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-94.
30. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721-4.
31. Morris AA. Mitochondrial respiratory chain disorders and the liver. Liver 1999; 19: 357-68.
32. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomalmitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008; 47: 1495-503.
33. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007; 31: S61-6.
34. Uzun MA, Koksal N, Kadioglu H, Gunerhan Y, Aktas S, Dursun N, et al. Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease. Surg Today 2009; 39: 592-7.
35. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
36. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-44.
37. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-50.
38. Yue J, Dong G, He C, Chen J, Liu Y, Peng R. Protective effects of thiopronin against isoniazid-induced hepatotoxicity in rats. Toxicology 2009; 264: 185-91.